Skip to main content
SpringerLink
Log in

The Patient With Type 1 Diabetes and Hypoglycemia

  • Chapter
Evidence-Based Endocrinology

Part of the book series: Contemporary Endocrinology ((COE))

  • 843 Accesses

Abstract

Type 1 diabetes (T1D) was fatal prior to the discovery of insulin in 1921. Insulin injections saved the lives of patients with T1D with a dramatic improvement in the symptoms of hyperglycemia and diabetic ketoacidosis (1). Vascular and neuropathic complications of T1D became apparent by the 1950s (2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Clarke B. Historical perspective. Hypoglycaemie and Diabetes: Clinical and Physiological Aspects. Edward Arnold, London, 1993, pp1–16.

    Google Scholar 

  2. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676–1685.

    Article  PubMed  CAS  Google Scholar 

  3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.

    Article  Google Scholar 

  4. The Diabetes Control and Complications Trial Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991;90:450–459.

    Google Scholar 

  5. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271–286.

    Article  Google Scholar 

  6. Tabak AG, Tamas G, Zgibor J, et al. Targets and reality: a comparison of health care indicators in the U.S. (Pittsburgh Epidemiology of Diabetes Complications Study) and Hungary (DiabCare Hungary). Diabetes Care 2000;23:1284–1289.

    Article  PubMed  CAS  Google Scholar 

  7. Barr CC. Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive insulin therapy, by the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381–389.

    Article  Google Scholar 

  8. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 1986;35:530–345.

    Article  PubMed  Google Scholar 

  9. Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care 1987;10:1–19.

    Google Scholar 

  10. Cox DJ, Gonder-Frederick L, Julian D, et al. Intensive versus standard blood glucose awareness training (BGAT) with insulin-dependent diabetes: mechanisms and ancillary effects. Psychosom Med 1991;53:453–462.

    PubMed  CAS  Google Scholar 

  11. Cox D, Gonder-Frederick L, Polonsky W, Schlundt D, Julian D, Clarke W. A multicenter evaluation of blood glucose awareness training-II. Diabetes Care 1995;18:523–528.

    Article  PubMed  CAS  Google Scholar 

  12. Cox DJ, Gonder-Frederick L, Polonsky W, Schlundt D, Kovatchev B, Clarke W. Blood glucose awareness training (BGAT-2): long-term benefits. Diabetes Care April 2001;24:637–642.

    Article  CAS  Google Scholar 

  13. Brunelle BL, Llewelyn J, Anderson JH, Jr., Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998;21:1726–1731.

    Article  PubMed  CAS  Google Scholar 

  14. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000;23:639–643.

    Article  PubMed  CAS  Google Scholar 

  15. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666–1671.

    Article  PubMed  CAS  Google Scholar 

  16. Rosenstock J, Park G, Zimmerman J, Group USIGTDI. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 2000;23:1137–1142.

    Article  PubMed  CAS  Google Scholar 

  17. Danne T, Lupke K, Walte K, Von Schuetz W, Gall MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003;26:3087–3092.

    Article  PubMed  CAS  Google Scholar 

  18. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19:644–55.

    PubMed  CAS  Google Scholar 

  19. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care 2000;23:1232–1235.

    Article  PubMed  CAS  Google Scholar 

  20. Eichner HL, Selam JL, Holleman CB, Worcester BR, Turner DS, Charles MA. Reduction of severe hypoglycemic events in type I (insulin dependent) diabetic patients using continuous subcutaneous insulin infusion. Diabetes Research 1988;8:189–193.

    PubMed  CAS  Google Scholar 

  21. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 1996;19:324–327.

    Article  PubMed  CAS  Google Scholar 

  22. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999;22:1779–1784.

    Article  PubMed  CAS  Google Scholar 

  23. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:705.

    Article  PubMed  CAS  Google Scholar 

  24. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003;26:1079–1087.

    Article  PubMed  Google Scholar 

  25. Anonymous. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:361–676.

    Google Scholar 

  26. Tsui E, Barnie A, Ross S, Parkes R, Zinman B. Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001;24:1722–1727.

    Article  PubMed  CAS  Google Scholar 

  27. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230–238.

    Article  PubMed  CAS  Google Scholar 

  28. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001;50:710–719.

    Article  PubMed  CAS  Google Scholar 

  29. Hirshberg B, Rother KI, Digon BJ, 3rd, et al. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care 2003;26:3288–3295.

    Article  PubMed  Google Scholar 

  30. Shapiro AM, Ricordi C, Hering B. Edmonton’s islet success has indeed been replicated elsewhere. Lancet 2003;362:1242.

    Article  PubMed  Google Scholar 

  31. Shapiro AM, Ricordi C. Unraveling the secrets of single donor success in islet transplantation. Am J Transplant 2004;4:295–298.

    Article  PubMed  Google Scholar 

  32. Kessler L, Passemard R, Oberholzer J, et al. Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation: interest of continuous glucose monitoring. Diabetes Care 2002;25:2256–2562.

    Article  PubMed  CAS  Google Scholar 

  33. Hering B, Kandasamy R, Harmon J, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004;4:390–401.

    Article  PubMed  CAS  Google Scholar 

  34. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of October 2002. Clin Transpl 2003;21–51.

    Google Scholar 

  35. Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA 2003;290:2817–2823.

    Article  PubMed  CAS  Google Scholar 

  36. Redmon JB, Teuscher AU, Robertson RP. Hypoglycemia after pancreas transplantation. Diabetes Care 1998;21:1944–1950.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Mayo Clinic College of Medicine, Rochester, MN

    Yogish C. Kudva MD, MBBS

  2. Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN

    Teck-Kim Khoo MD

  3. Division of Pediatric Endocrinology, Department of Adolescent and Pediatric Medicine, Mayo Clinic College of Medicine, Rochester, MN

    Peter J. Tebben MD

Authors
  1. Yogish C. Kudva MD, MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teck-Kim Khoo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter J. Tebben MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mayo Clinic College of Medicine, Rochester, MN

    Victor M. Montori MD, MSc

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Mayo Foundation for Medical Education and Research

About this chapter

Cite this chapter

Kudva, Y.C., Khoo, TK., Tebben, P.J. (2006). The Patient With Type 1 Diabetes and Hypoglycemia. In: Montori, V.M. (eds) Evidence-Based Endocrinology. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-008-9_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-008-9_17

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-579-8

  • Online ISBN: 978-1-59745-008-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation